Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals PLC    HIK   GB00B0LCW083

HIKMA PHARMACEUTICALS PLC

(HIK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/22/2021 01/25/2021 01/26/2021 01/27/2021 01/28/2021 Date
2518(c) 2494(c) 2471(c) 2430(c) 2457 Last
237 974 387 167 603 330 535 257 150 212 Volume
-0.67% -0.95% -0.92% -1.66% +1.11% Change
More quotes
Financials (USD)
Sales 2020 2 329 M - -
Net income 2020 400 M - -
Net Debt 2020 357 M - -
P/E ratio 2020 19,8x
Yield 2020 1,46%
Sales 2021 2 501 M - -
Net income 2021 421 M - -
Net Debt 2021 117 M - -
P/E ratio 2021 18,5x
Yield 2021 1,60%
Capitalization 7 654 M 7 675 M -
EV / Sales 2020 3,44x
EV / Sales 2021 3,11x
Nbr of Employees 8 600
Free-Float 67,7%
More Financials
Company
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (40.5%); - generic products taken orally (32.6%); - brand name drugs (26.4%); - other (0.5%). Net sales are distributed geographically as follows: the United Kingdom... 
More about the company
Notations Surperformance© of Hikma Pharmaceuticals PLC
Trading Rating : Investor Rating :
More Ratings
All news about HIKMA PHARMACEUTICALS PLC
01/27HIKMA PHARMACEUTICALS : Potential Acquisition
AQ
01/26Hikma plans to buy some of GSK's assets in Egypt, Tunisia
RE
01/26GLAXOSMITHKLINE : Hikma in Talks to Acquire GlaxoSmithKline Assets in Egypt, Tun..
MT
01/26HIKMA PHARMACEUTICALS : Confirms Potential Acquisition of GSK's Egypt, Tunisia O..
MT
01/26HIKMA PHARMACEUTICALS : Says It Is in Talks With GlaxoSmithKline to Buy Some Bus..
DJ
01/25CAPLIN POINT LABORATORIES : Gets US FDA Approval for Anticoagulant Injection
MT
01/21NY governor investigates price jump in six drugs during pandemic
RE
01/18HIKMA PHARMACEUTICALS : provides update on generic Advair Diskus launch
AQ
01/17HIKMA PHARMACEUTICALS : Pauses Asthma Drug Launch to Amend US FDA Application
MT
01/14HIKMA PHARMACEUTICALS : commitment to environmental performance recognised with ..
AQ
01/12Vectura Expects 2020 Revenue, Adjusted EBITDA To Beat Estimates On US Approva..
MT
2020Vectura earns $11m milestone as Hikma receives US FDA approval for generic Ad..
AQ
2020HIKMA PHARMACEUTICALS : launches generic Advair Diskus following FDA approval
AQ
2020Hikma Wins US Regulatory Approval For Generic Asthma Drug
MT
2020HIKMA PHARMACEUTICALS PLC : Crossing thresholds
CO
More news
News in other languages on HIKMA PHARMACEUTICALS PLC
2020AVIS D'ANALYSTES DU JOUR : Alcon, BMW, Delivery Hero, Getlink, Logitech, Rubis, ..
2020AVIS D'ANALYSTES DU JOUR : EDF, Hikma, Innate Pharma, Natixis, Rio Tinto, Roche,..
2020AVIS D'ANALYSTES DU JOUR : Adyen, Amadeus, Capgemini, Casino, Logitech, Michelin..
2020LONDON STOCK EXCHANGE : Londres portée par les annonces de Trump
2020LONDON STOCK EXCHANGE : Londres optimiste sur la reprise économique
More news
Analyst Recommendations on HIKMA PHARMACEUTICALS PLC
More recommendations
Stock Trading Strategies
HIKMA PHARMACEUTICALS PLC - 2020
Technically solid
BUY
More Stock Trading Analysis
Chart HIKMA PHARMACEUTICALS PLC
Duration : Period :
Hikma Pharmaceuticals PLC Technical Analysis Chart | HIK | GB00B0LCW083 | MarketScreener
Technical analysis trends HIKMA PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 35,32 $
Last Close Price 33,21 $
Spread / Highest target 24,2%
Spread / Average Target 6,33%
Spread / Lowest Target -42,7%
EPS Revisions
Managers and Directors
NameTitle
Sigurdur Oli Olafsson Chief Executive Officer & Director
Said Samih Taleb Darwazah Executive Chairman
Henriette Nielsen Executive Vice President-Business Operations
Khalid Walid Hosni Nabilsi Chief Financial Officer
Bryan Hotston Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
HIKMA PHARMACEUTICALS PLC-3.49%7 675
JOHNSON & JOHNSON6.67%441 951
ROCHE HOLDING AG3.62%309 011
NOVARTIS AG0.20%212 810
PFIZER INC.-1.55%201 436
MERCK & CO., INC.-5.78%194 990